The global central nervous therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period (2022-2028). The growing number of central nervous disorders across the globe is significantly contributing to the growth of the global central nervous system therapeutic market. The prevalence of Alzheimer’s disease, multiple sclerosis, epilepsy, Parkinson’s disease, mental health and stroke are significantly growing across the globe. For instance, as per the World Health Organization (WHO), epilepsy is a chronic non-communicable disease of the brain which affects the brain around 50 million people across the globe are suffering from this disease and is one of the most common neurological diseases. Depression is a common mental disorder, around 5% of adults across the globe suffered from depression. It is a leading cause of disability across the globe. This, in turn, is driving the demand for treatment for these disorders, which in turn, is accelerating the market growth.
Browse the full report description of “Central Nervous System Therapeutic Market Size, Share and Trends Analysis Report, By Indication (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, and Cancer), By Application (Hospital and Clinic, Homecare, and Others), By Drug Class (Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, and Others), Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/central-nervous-system-therapeutic-market
Some new launches of CNS drugs have been witnessed across the globe. For instance, in April 2021, Optimus Pharma announced that it has received approval for its Anti-Parkinson drug Safinamide in India. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes. Optimus believes Safinamide will give an additional option to healthcare professionals in the treatment of Parkinson's and improve the quality of life of millions who are affected by Parkinson's disease. A homegrown generic version of Safinamide developed by Optimus will assist in delivering robust treatment for Parkinson's diseases in India with very high affordability and accessibility.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Indication
o By Application
o By Drug Class
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Biogen Inc., and Eli Lilly, and Company Inc.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Çentral Nervous Therapeutic Market Report by Segment
By Indication
By Application
By Drug Class
Global Çentral Nervous Therapeutic Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/central-nervous-system-therapeutic-market